大肠肿瘤p53和ki-ras基因协同突变的研究

目的探讨大肠肿瘤p53和ki-ras基因协同突变的临床意义。方法采用免疫组化和PCR-SSCP方法,检测58例大肠肿瘤患者的良性病变、良性病变转为恶变、原发腺癌组织的p53基因、ki-ras基因的表达和突变情况。结果良性病变组与恶变组间的p53基因和Ki-ras基因的表达有显著差异,良性病变组与原发腺癌组的Ki-ras基因表达差异显著;良性病变组的p53基因与Ki-ras基因的表达呈负相关,而恶变组和原发腺癌组呈正相关。p53基因和ki-ras基因两种基因突变率无显著差异,而协同突变与淋巴结转移密切相关,相关系数r=0.335,P=0.017,P0.05。结论 p53和ki-ras基因协同突变可以促进了大肠癌的发展。监测p53基因和Ki-ras基因的协同表达和突变,有助于大肠肿瘤的早期诊断和预后评价。

Collaborative mutation of p53 and ki-ras genes in colorectal cancer

Objective To explore p53 and ki：ras genes collaborative mutation in colorectal cancer patients.Methods The p53 gene and ki-ras gene expression and mutation were detected in 58 cases of colorectal cancer patients with benign lesions, benign lesions to malignant, primary adenocarcinoma by immunohistochemical staining and PCR-SSCP method respectively. Results The Expressions of P53 gene and Ki-ras gene were significantly different between benign group and malignant group. The Ki-ras gene expression of benign lesions and primary adenocarcinoma was significantly different. And in benign lesions, the expression of the 1953 gene and Ki-ras gene was negatively correlated, while the malignant group and the primary adenocarcinoma showed positive correlation. The mutations between 1：53 gene and ki-ras gene was no significant difference in a concerted mutation. Synergistic gene mutation of p53 gene and ki-ras gene is closely related to lymph node metastasis. R = 0.335, P = 0. 017, P 〈 0.05. Conclusion p53 and ki-ras gene mutation can contribute to the synergy of colorectal cancer development. Monitoring the P53 gene and Ki-ras gene expression and mutation of the synergy will help the early diagnosis and prognosis in colorectal cancer patients.